BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17151928)

  • 1. Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers.
    Pepe C; Guidugli L; Sensi E; Aretini P; D'Andrea E; Montagna M; Manoukian S; Ottini L; Radice P; Viel A; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2007 May; 103(1):29-36. PubMed ID: 17151928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer.
    Beetstra S; Suthers G; Dhillon V; Salisbury C; Turner J; Altree M; McKinnon R; Fenech M
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2565-71. PubMed ID: 18842997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiński J; Scott RJ; Hamann U
    Breast Cancer Res Treat; 2007 Sep; 104(3):299-308. PubMed ID: 17063264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
    Hughes DJ; Ginolhac SM; Coupier I; Corbex M; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Maugard C; Olschwang S; Yannoukakos D; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Szabo C; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):265-7. PubMed ID: 15668505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: a case-control study in Taiwan.
    Chou YC; Wu MH; Yu JC; Lee MS; Yang T; Shih HL; Wu TY; Sun CA
    Carcinogenesis; 2006 Nov; 27(11):2295-300. PubMed ID: 16777985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-carbon metabolism-related gene polymorphisms and risk of breast cancer.
    Suzuki T; Matsuo K; Hirose K; Hiraki A; Kawase T; Watanabe M; Yamashita T; Iwata H; Tajima K
    Carcinogenesis; 2008 Feb; 29(2):356-62. PubMed ID: 18174236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
    King MC; Marks JH; Mandell JB;
    Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers.
    Catucci I; Verderio P; Pizzamiglio S; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Ripamonti CB; Pasini B; Barile M; Viel A; Giannini G; Papi L; Varesco L; Martayan A; Riboni M; Volorio S; Radice P; Peterlongo P
    Breast Cancer Res Treat; 2011 Feb; 125(3):855-60. PubMed ID: 20652397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
    Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
    Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
    Phelan CM; Rebbeck TR; Weber BL; Devilee P; Ruttledge MH; Lynch HT; Lenoir GM; Stratton MR; Easton DF; Ponder BA; Cannon-Albright L; Larsson C; Goldgar DE; Narod SA
    Nat Genet; 1996 Mar; 12(3):309-11. PubMed ID: 8589723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate intake, methylenetetrahydrofolate reductase polymorphisms, and breast cancer risk in women from the Malmö Diet and Cancer cohort.
    Ericson U; Sonestedt E; Ivarsson MI; Gullberg B; Carlson J; Olsson H; Wirfält E
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1101-10. PubMed ID: 19336565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.
    Paz MF; Avila S; Fraga MF; Pollan M; Capella G; Peinado MA; Sanchez-Cespedes M; Herman JG; Esteller M
    Cancer Res; 2002 Aug; 62(15):4519-24. PubMed ID: 12154064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
    Ginolhac SM; Gad S; Corbex M; Bressac-De-Paillerets B; Chompret A; Bignon YJ; Peyrat JP; Fournier J; Lasset C; Giraud S; Muller D; Fricker JP; Hardouin A; Berthet P; Maugard C; Nogues C; Lidereau R; Longy M; Olschwang S; Toulas C; Guimbaud R; Yannoukakos D; Szabo C; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Goldgar D; Stoppa-Lyonnet D; Lenoir GM; Sinilnikova OM
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):90-5. PubMed ID: 12582017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer.
    Li SY; Rong M; Iacopetta B
    Oncol Rep; 2006 Jan; 15(1):221-5. PubMed ID: 16328059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevalence of Val158Met polymorphism in COMT gene on non-BRCA1/2 hereditary breast cancer].
    Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
    Zhonghua Wai Ke Za Zhi; 2006 Oct; 44(19):1310-3. PubMed ID: 17217814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.